{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:44:37Z","timestamp":1769975077337,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s41669-018-0110-3","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T08:24:07Z","timestamp":1544775847000},"page":"351-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q"],"prefix":"10.1007","volume":"3","author":[{"given":"Dawn","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nic","family":"Brereton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujith","family":"Dhanasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Kulasekararaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"110_CR1","unstructured":"Celgene Ltd. Revlimid\u00ae. Summary of product characteristics. 2014. \n                    http:\/\/www.medicines.org.uk\/emc\/medicine\/19841\/SPC\/Revlimid\n                    \n                  . Accessed 13 Jan 2015."},{"key":"110_CR2","doi-asserted-by":"crossref","unstructured":"Besa EC. Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues. Med Clin North Am. 1992;76(3):599\u2013617.","DOI":"10.1016\/S0025-7125(16)30342-X"},{"key":"110_CR3","doi-asserted-by":"crossref","unstructured":"List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004:297\u2013317.","DOI":"10.1182\/asheducation-2004.1.297"},{"issue":"10","key":"110_CR4","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/cncr.21860","volume":"106","author":"L Balducci","year":"2006","unstructured":"Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006;106(10):2087\u201394.","journal-title":"Cancer"},{"issue":"1","key":"110_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/leu.2010.231","volume":"25","author":"M Mallo","year":"2011","unstructured":"Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Lu\u00f1o E, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011;25(1):110\u201320.","journal-title":"Leukemia"},{"issue":"2","key":"110_CR6","first-page":"160","volume":"1","author":"EN Oliva","year":"2011","unstructured":"Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res. 2011;1(2):160.","journal-title":"Am J Blood Res."},{"issue":"8","key":"110_CR7","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1185\/03007990903076699","volume":"25","author":"JR Frytak","year":"2009","unstructured":"Frytak JR, Henk HJ, De Castro CM, Halpern R, Nelson M. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin. 2009;25(8):1941\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"110_CR8","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","volume":"96","author":"L Malcovati","year":"2011","unstructured":"Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433\u201340.","journal-title":"Haematologica"},{"issue":"2","key":"110_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1524-4733.2005.03089.x","volume":"8","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health. 2005;8(2):149\u201356.","journal-title":"Value Health."},{"issue":"4","key":"110_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-3148.2003.00443.x","volume":"13","author":"SJ Varney","year":"2003","unstructured":"Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med. 2003;13(4):205\u201318.","journal-title":"Transfus Med"},{"issue":"14","key":"110_CR11","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765\u201376.","journal-title":"Blood"},{"key":"110_CR12","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. \n                    https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword\n                    \n                  . Accessed 6 Jan 2016."},{"key":"110_CR13","unstructured":"HM Treasury. The green book. Central government guidance on appraisal and evaluation. OGL; 2018."},{"issue":"1","key":"110_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","volume":"111","author":"A Raza","year":"2008","unstructured":"Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1\u2013risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86\u201393.","journal-title":"Blood"},{"issue":"21","key":"110_CR15","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood.V122.21.2770.2770","volume":"122","author":"L Swart De","year":"2013","unstructured":"De Swart L, Smith A, Johnston T, Haase D, Droste J, Fenaux P, et al. Validation of the Revised International Prognostic Scoring System (IPSS-R) in 1000 newly diagnosed MDS patients with Low- and Intermediate-1 risk MDS in the European Leukemianet MDS (EUMDS) Registry. Blood. 2013;122(21):2770 (Abstract).","journal-title":"Blood"},{"issue":"6","key":"110_CR16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079\u201388.","journal-title":"Blood"},{"issue":"1","key":"110_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000445163","volume":"136","author":"S Harnan","year":"2016","unstructured":"Harnan S, Ren S, Gomersall T, Everson-Hock ES, Sutton A, Dhanasiri S, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol. 2016;136(1):23\u201342.","journal-title":"Acta Haematol"},{"issue":"5","key":"110_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/ejh.12380","volume":"93","author":"A Giagounidis","year":"2014","unstructured":"Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, et al. Outcomes in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol. 2014;93(5):429\u201338.","journal-title":"Eur J Haematol"},{"issue":"5","key":"110_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/leu.2013.305","volume":"28","author":"AF List","year":"2014","unstructured":"List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28(5):1033\u201340.","journal-title":"Leukemia"},{"issue":"21","key":"110_CR20","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1002\/cncr.28298","volume":"119","author":"AM Zeidan","year":"2013","unstructured":"Zeidan AM, Gore SD, McNally DL, Baer MR, Hendrick F, Mahmoud D, et al. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013;119(21):3870\u20138.","journal-title":"Cancer"},{"key":"110_CR21","unstructured":"National Institute for Health and Care Excellence. TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. 2014. \n                    https:\/\/www.nice.org.uk\/guidance\/ta319\n                    \n                  . Accessed 8 Jan 2015."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-018-0110-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-018-0110-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-018-0110-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T19:09:59Z","timestamp":1576264199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-018-0110-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1007\/s41669-018-0110-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]},"assertion":[{"value":"14 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dawn Lee and Nic Brereton are employed by BresMed Health Solutions Ltd, a consultancy company that was commissioned by Celgene Corporation to perform the reported analysis. Sujith Dhanasiri is an employee of Celgene Corporation, which funded this study. Austin Kulasekararaj received honorarium, consulting fees and payment for lectures and educational meetings from Celgene Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Celgene Corporation provided funding for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data requests may be submitted to Celgene at  and must include a description of the research proposal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}